Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 6/20 | 0.44 |
| ▸ | FPR2 | P25090 | 6/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718379 | 0.83 | MGLL (0.42) | RAB9ASMN1; SMN2MGLLALDH1A1MAPT | |
| SCHEMBL5154917 | 0.83 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2CA12CA1 | |
| SCHEMBL16585185 | 0.81 | IDO1 (0.41) | CA12CA1CA2CA9AAK1 | |
| SCHEMBL16592969 | 0.80 | EPAS1 (0.39) | NPC1RECQLRAB9ASMN1; SMN2FPR3 | |
| SCHEMBL16584931 | 0.79 | AAK1 (0.54) | NPC1RECQLRAB9ASMN1; SMN2AAK1 | |
| SCHEMBL15739789 | 0.77 | AAK1 (0.55) | CA12CA1CA2CA9AAK1 | |
| SCHEMBL29134875 | 0.77 | NPC1 (0.46) | NPC1RECQLRAB9ASMN1; SMN2FPR3 | |
| SCHEMBL12227490 | 0.77 | CA12 (0.67) | NPC1RECQLRAB9ASMN1; SMN2FPR3 | |
| SCHEMBL4969884 | 0.75 | CA12 (0.68) | FPR3FPR2CA12CA1CA2 | |
| SCHEMBL21991272 | 0.75 | HPGD (0.44) | RAB9ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | CYP11B2, CYP11B1, SLC10A1 | NPC1 92/4885RECQL 3276/4885RAB9A 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.